Affimed
Affimed is a clinical-stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies.
The German company's product candidates are being developed in the field of immuno-oncology and in total it has six assets in its pipeline.
In August 2018, Affimed signed a deal with Roche's Genentech unit that is worth $96 million up front, but with milestone payments and royalties could total up to $5 billion. The companies will develop and market novel NK cell engager-based drugs to treat several cancers.
Latest Affimed News & Features
13 December 2022
3 November 2022
12 August 2022
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze